Optimized BCMA/CS1 bispecific TRuC-T cells secreting IL-7 and CCL21 robustly control multiple myeloma
This study demonstrated that BC-7×21 TRuC-T cells, engineered through the optimization of the two subunits of TCR/CD3 complex and a co-expression cytokine strategy, may offer a novel and effective therapy for relapsed/refractory multiple myeloma.
Authors
- Peiyuan Zhang (ORCID: https://orcid.org/0000-0003-4086-3436)
- Rong Zheng (ORCID: https://orcid.org/0000-0002-9605-450X)
- Ai Zhao (ORCID: https://orcid.org/0000-0001-8357-594X)
- Xueyi Xin
- Zairu Liu
- Tingwei Zhu (ORCID: https://orcid.org/0000-0002-6962-6330)
- Binjiao Zheng
- Jimin Gao (ORCID: https://orcid.org/0000-0002-3911-043X)
- Hongli Zhao (ORCID: https://orcid.org/0000-0002-6558-5009)
- Wen-Yi Chen (ORCID: https://orcid.org/0009-0000-3981-478X)
- Min Li (ORCID: https://orcid.org/0000-0001-8786-5629)
Institutions
- Wenzhou Medical University (CN)
- Westlake University (CN)
- Taizhou Central Hospital (CN)
- Affiliated Hangzhou First People's Hospital, Westlake University, School of Medicine (CN)
- Taizhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-12-24
- DOI
- https://doi.org/10.3389/fimmu.2024.1502936
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.57
Funders
- Wenzhou Medical University
- Natural Science Foundation of Guangdong Province